Results 241 to 250 of about 61,117 (342)

Correction to: Clinical implications of mineralocorticoid receptor overactivation. [PDF]

Clin Kidney J
europepmc   +1 more source

Aldosterone Breakthrough for the Prediction of Treatment Response to Mineralocorticoid Receptor Antagonists. [PDF]

Kidney Med
Imcaoudene AR, Najjar C, Marques P, Tsoukas MA, Sharma A, Mavrakanas TA.   +5 more
europepmc   +1 more source

The Effect of Mineralocorticoid Receptor Antagonists on Heart Failure with Nonreduced Ejection Fraction: A Systematic Review and Meta-Analysis. [PDF]

CJC Open
De Luca C, Bhatt H, Gupta A, Yahyavi A, Banivaheb B, Rayner D, Anderson K, Zieroth S, Virani SA, Foroutan F, Aleksova N.   +10 more
europepmc   +1 more source

Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double‐blind, placebo‐controlled, phase 3 trial (SYNCHRONIZE™‐1)

Diabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 337-346, January 2026.
Abstract Aims Survodutide, a novel glucagon receptor and glucagon‐like peptide‐1 (GLP‐1) receptor dual agonist, elicited significant weight loss in a phase 2 trial in individuals with obesity without type 2 diabetes (T2D). Two multinational phase 3 trials are investigating survodutide for obesity management in individuals with or without T2D. We report
Carel W. le Roux, Sean Wharton, Biykem Bozkurt, Elke Platz, Gabriele Bleckert, Samina Ajaz Hussain, Martina Brueckmann, Elena Startseva, Isabel M. Kloer, Lee M. Kaplan   +9 more
wiley   +1 more source

Mineralocorticoid Receptor in Glutamatergic Neurons Modulates Anxiety Exclusively in Male Mice Via Regulation of the Actin-Bundling Factor Fam107a. [PDF]

Biol Psychiatry Glob Open Sci
Yang H, Narayan S, Bordes J, van Doeselaar L, De Donno C, Eder M, Menegaz D, Huettl RE, Brix LM, Mitra S, Springer M, Müller MB, Chen A, Deussing JM, Lopez JP, Schmidt MV.   +15 more
europepmc   +1 more source

Mineralocorticoid receptor antagonists in the treatment of patients with chronic heart failure. Positions in 2015

, 2015
Yu. F. Osmolovskaya, И. В. Жиров, С. Н. Терещенко   +2 more
openalex   +1 more source

IL‐6 in the spotlight: From cardiovascular pathophysiology to therapy

European Journal of Clinical Investigation, Volume 56, Issue 1, January 2026.
Interleukin‐6 (IL‐6) links inflammation to cardiovascular and multi‐organ dysfunction. This review integrates mechanistic, translational, and clinical evidence supporting IL‐6 as both a biomarker and therapeutic target in the continuum of cardiovascular and cardio‐renal disease.
Alberto Preda, Amedeo Tirandi, Giulio Leo, Davide Di Vece, Gemma Vilahur, Aldo Bonaventura, Elena Osto, Stefano Ministrini, Simon Kraler, Petra Kleinbogard, Giovanni Camici, Federico Carbone, Fabrizio Montecucco, Luca Liberale   +13 more
wiley   +1 more source

Mineralocorticoid receptor antagonism prevents coronary microvascular dysfunction in intermittent hypoxia independent of blood pressure. [PDF]

Sleep
Badran M, Khalyfa A, Bailey CA, Gozal D, Bender SB.   +4 more
europepmc   +1 more source

Trained Immunity and Cardiovascular Risk: An Immunological Perspective

Immunological Reviews, Volume 337, Issue 1, January 2026.
ABSTRACT Systemic inflammation is a key driver of atherogenesis and its complications. While anti‐inflammatory therapies targeting pathways such as IL‐1β and IL‐6 have shown promise in established atherosclerotic cardiovascular disease (ASCVD), potential systemic effects raise concerns about immune suppression and infection, underscoring the need for ...
Katherine A. Boden, Jason Chai, Tafadzwa T. J. Kufazvinei, Robin P. Choudhury   +3 more
wiley   +1 more source

Adrenal venous sampling outcomes with and without mineralocorticoid receptor antagonists in primary aldosteronism. [PDF]

BMC Endocr Disord
Thipbumrung S, Manosroi W.
europepmc   +1 more source